Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
Veringa A, Brüggemann RJ, Span LFR, Biemond BJ, de Boer MGJ, van den Heuvel ER, Klein SK, Kraemer D, Minnema MC, Prakken NHJ, Rijnders BJA, Swen JJ, Verweij PE, Wondergem MJ, Ypma PF, Blijlevens N, Kosterink JGW, van der Werf TS, Alffenaar JC; Voriconazole ZonMw Study Group. Veringa A, et al. Among authors: rijnders bja. Int J Antimicrob Agents. 2023 Feb;61(2):106711. doi: 10.1016/j.ijantimicag.2023.106711. Epub 2023 Jan 13. Int J Antimicrob Agents. 2023. PMID: 36642232 Free article. Clinical Trial.
Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.
van de Sande WW, Mathot RA, ten Kate MT, van Vianen W, Tavakol M, Rijnders BJ, Bakker-Woudenberg IA. van de Sande WW, et al. Antimicrob Agents Chemother. 2009 May;53(5):2005-13. doi: 10.1128/AAC.01556-08. Epub 2009 Feb 23. Antimicrob Agents Chemother. 2009. PMID: 19237647 Free PMC article.
Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J, Karawajczyk A, Zoll J, Melchers WJ, Verweij PE. van der Linden JW, et al. Clin Infect Dis. 2013 Aug;57(4):513-20. doi: 10.1093/cid/cit320. Epub 2013 May 10. Clin Infect Dis. 2013. PMID: 23667263
Influenza-Associated Aspergillosis in Critically Ill Patients.
van de Veerdonk FL, Kolwijck E, Lestrade PP, Hodiamont CJ, Rijnders BJ, van Paassen J, Haas PJ, Oliveira Dos Santos C, Kampinga GA, Bergmans DC, van Dijk K, de Haan AF, van Dissel J, van der Hoeven HG, Verweij PE; Dutch Mycoses Study Group. van de Veerdonk FL, et al. Am J Respir Crit Care Med. 2017 Aug 15;196(4):524-527. doi: 10.1164/rccm.201612-2540LE. Epub 2017 Apr 7. Am J Respir Crit Care Med. 2017. PMID: 28387526 No abstract available.
The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol.
Schauwvlieghe AFAD, de Jonge N, van Dijk K, Verweij PE, Brüggemann RJ, Biemond BJ, Bart A, von dem Borne PA, Verbon A, van der Beek MT, Demandt AMP, Oudhuis GJ, Cornelissen JJ, van der Velden WJFM, Span LFR, Kampinga GA, Bruns AH, Vonk AG, Haas PA, Doorduijn JK, Rijnders BJA. Schauwvlieghe AFAD, et al. Among authors: rijnders bja. Mycoses. 2018 Sep;61(9):656-664. doi: 10.1111/myc.12788. Epub 2018 Jul 13. Mycoses. 2018. PMID: 29687483
200 results